TABLE 1

Study outlines of PF06463922 and PF06471402 in athymic mice implanted with H3122 non–small cell lung carcinomas expressing EML4-ALK^L1196M

ALK Inhibitor	Study	Dosing Route	Dosing Regimen	Dose Amount
				mg/kg daily
PF06463922	1^{^a}	p.o.	Twice daily, 7 h apart	0.6–40
	2	s.c.	Constant infusion	0.5–40
PF06471402	3	p.o.	Twice daily, 7 h apart	1.2–60
	4	s.c.	Constant infusion	0.5–50

p.o., oral administration by gavage; s.c., subcutaneous constant infusion via ALZET osmotic pumps at the infusion rate of 0.5 μl/h.
↵^a The results of study 1 have been reported in the previous report (Yamazaki et al., 2014).